Key result
Cobalt-II complexes outperform reference drugs against K pneumoniae with a ~22 mm inhibitory zone.
The synthesized coumarin-derived Cobalt(II) complex and heterocyclic derivatives demonstrate significant antimicrobial activity against S. aureus and K. pneumoniae, outperforming standard antibiotics in vitro and in silico.
Hypothesis-generating for cobalt-coumarin antimicrobials; requires in vivo validation before clinical consideration.
This study describes a multi-step synthetic protocol for constructing a coumarin-based scaffold, subsequently functionalized into a versatile Schiff base intermediate. This precursor served as a foundational unit for synthesizing a series of novel heterocyclic derivatives through five distinct cyclization strategies. A specific derivative was coordinated as a bidentate ligand to yield a novel Cobalt (II) complex (Q11). Comprehensive characterization via molar conductivity and magnetic susceptibility confirmed the formation of a non-electrolytic complex, while FE-SEM analysis revealed its nanostructured nature. Spectroscopic data (µeff = 1.95 B.M.) corroborated a rare low-spin, tetragonally distorted octahedral (D4h) geometry with a (t2g6eg1) geometry for the Cobalt complex. The antimicrobial screening of the synthesized heterocyclic derivatives and the Cobalt(II) complex against Gram-positive Staphylococcus aureus and Gram-negative Klebsiella pneumoniae revealed significant biological potency. Notably, compounds (Q5-Q6) exhibited larger inhibitory zones than the antibiotic control, while the nanostructured complex (Q11) demonstrated superior activity, particularly against the resistant K. pneumoniae strain (22 mm). In addition, molecular docking simulations were performed for these derivatives against bacterial DNA gyrase targets (PDB IDs: 2XCT and 4DX5). The results revealed exceptional binding affinities of -10.6 kcal/mol for Q5 and -10.2 kcal/mol for Q6, significantly outperforming the reference drugs Ciprofloxacin and Ceftriaxone. A high correlation was observed between the in silico binding energies and the in vitro results. These findings, highlighting the superior potency of the nanostructured complex in overcoming diverse membrane barriers of both Gram-positive and Gram-negative bacteria, position this series as a promising candidate for high-surface-area catalysis and advanced biomedical applications.
No takes yet. Share an insight, caveat, or question.
Almolah et al. (2026) studied Bacterial infection (Staphylococcus aureus, Klebsiella pneumoniae). Cobalt(II) complex (Q11) and coumarin-based heterocyclic derivatives vs. Antibiotic control (Ciprofloxacin and Ceftriaxone) was evaluated on Antimicrobial inhibitory zones and molecular docking binding affinities. The Cobalt(II) complex (Q11) and derivatives Q5-Q6 showed superior antimicrobial activity against K. pneumoniae (22 mm zone) and binding affinities (-10.6 kcal/mol) compared to reference drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: